Acticor Biotech winner of the Prix Galien Medstartup in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGICAL INDUSTRY”,organized by the prestigious Galien Foundation and by Business France. Read the press release Acticor Biotech announces FDA acceptance of its IND Application for Glenzocimab in Acute Ischemic Stroke Read the press release
A 2-year postdoctoral position is available in the Basophils, Mast cells and Immunopathology (BMI) team of the Centre for Research on Inflammation (CRI, INSERM U1149 CNRS ERL8252 University of Paris, Laboratoire d’Excellence INFLAMEX) at the Bichat Medical School, University of Paris, in Paris, France. The expected starting date is January, 1st 2022. Read the full description of the proposal.
miRNA Delivery by Nanosystems: State of the Art and Perspectives Moraes FC, Pichon C, Letourneur D, Chaubet F 2021 •Pharmaceutics • [pdf] MicroRNAs (miRNAs) are short (~21–23 nucleotides), non-coding endogenous RNA molecules that modulate gene expression at the post-transcriptional level via the endogenous RNA interference machinery of the cell. They have emerged as potential biopharmaceuticals candidates for the treatment of various… Read more »
L’institut des Sciences Cardiovasculaires — auquel le LVTS participe — s’associe à l’organisation de la conférence Biomarker of the Future 2021. Deux prix Jeunes chercheurs seront également attribués. Le site web de la conférence (pour info & inscriptions) : www.biomarkersofthefuture.com Ou plus d’informations sur le site de l’institut : https://www.institutcardiovasculaireparis.fr/ BMF 21 Program